SOMAÍ Prescribed drugs (“SOMAÍ”), a vertically built-in Multi-Nation Operator (MCO) within the international medical hashish markets, is proud to announce the launch of the Mint Oral Options product line in Australia, Germany and the UK.
SOMAÍ always focuses on the wants and preferences of sufferers to supply revolutionary merchandise, improved efficiency and style. The brand new line contains single-strain oils infused with peppermint terpene blends in numerous dosage types, from CBD-dominant to balanced and excessive THC. The mint line is the primary introduction to enhance affected person compliance and therapy adherence, combining purified extracts and a delicate fragrant mint taste.
“Hashish sufferers prioritize the efficiency, scent and style of the merchandise,” mentioned Michael Sassano, the founder and interim CEO of SOMAI Prescribed drugs. “So, as we prioritize bettering the affected person expertise, peppermint is a wonderful beginning expertise as a well-liked mix with calming and therapeutic results, in addition to a delicate nice style.”
Earlier this 12 months, SOMAÍ launched its first line of better-tasting Oral Options Necessities merchandise. October will showcase the following technology Origins strains and Senses strains of oral extracts and full inhalation strains. With greater than 100 extracted merchandise out and in of stability, together with inhalation oils, oral sprays, gentle gel capsules and oral gums with numerous terpene blends, extra superior formulations will quickly be on world markets. At the moment, the corporate is current within the Australian, German and British markets and can quickly launch in six different nations in Q3/4 2024.
